© 2000 European Society of Cardiology
Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART
Academic Department of Cardiology, University of Hull Castle Hill Hospital, Castle Road, Kingston upon Hull HU16 5JQ, UK
* Corresponding author. Tel.: +44-1482-623732; fax: +44-1482-624087. E-mail address: g.m.porter{at}medschool.hull.ac.uk (K. Witte).
 |
Abstract |
|---|
Important new studies relevant to the field of heart failure reported at the annual congress of the European Society of Cardiology (ESC), held in Amsterdam in August 2000, are reviewed. The IMPROVEMENT of Heart Failure survey investigated the knowledge and perceptions of over 1300 primary care physicians from 14 ESC member nations and the actual practice in over 11000 of their patients. Guidelines and clinical practice were compared. The survey suggested, in this large sample, that the quality of care was higher than previous smaller surveys have suggested but have also identified important deficiencies in knowledge and management that should be rectified. The COPERNICUS study demonstrated that carvedilol was remarkably well tolerated even in patients with very severe heart failure and that treatment was associated with a substantial reduction in mortality even among patients that would conventionally not be considered, by many, for beta-blocker therapy. The MUSTIC trial suggested that cardiac resynchronisation using biventricular pacing improved patients symptomatically whether or not the patient was in atrial fibrillation. Morbidity and mortality studies of cardiac resynchronisation are now underway. The ASPECT-II and APRICOT-II studies investigated the role of warfarin, aspirin and their combination for the long-term management of myocardial infarction. One interpretation of the data from these studies is that the combination of aspirin and warfarin is about as effective as warfarin alone but with a much higher incidence of side effects. Warfarin alone appeared superior to aspirin alone. In summary, the annual congress of the ESC provided important new information for clinical practice and, to date, was, by far, the most important cardiology congress in the world this year.
Key Words: Heart failure • Beta-blocker therapy • Warfarin • Aspirin
Received September 8, 2000; Accepted September 12, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R S Gardner, W Martin, R Carter, and T A McDonagh Importance of {beta} blockade in the treatment of advanced heart failure Heart, December 1, 2003; 89(12): 1442 - 1444. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G.F. Cleland, J. Ghosh, N. K. Khan, S. Ghio, L. Tavazzi, and G. Kaye Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony? Eur. Heart J., March 1, 2003; 24(5): 384 - 390. [Full Text] [PDF]
|
|
|
|
 |
|
 N. A Turner, K. E Porter, W. H.T Smith, H. L White, S. G Ball, and A. J Balmforth Chronic {beta}2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism Cardiovasc Res, March 1, 2003; 57(3): 784 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Anand and S. Yusuf Oral anticoagulants in patients with coronary artery disease J. Am. Coll. Cardiol., February 19, 2003; 41(4_Suppl_S): 62S - 69S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P A Poole-Wilson, B F Uretsky, K Thygesen, J G F Cleland, B M Massie, and L Ryden Mode of death in heart failure: findings from the ATLAS trial Heart, January 1, 2003; 89(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Muntwyler, G. Abetel, C. Gruner, and F. Follath One-year mortality among unselected outpatients with heart failure Eur. Heart J., December 1, 2002; 23(23): 1861 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Groenning, J. C. Nilsson, P. R. Hildebrandt, A. Kjaer, T. Fritz-Hansen, H. B.W. Larsson, and L. Sondergaard Neurohumoral prediction of left-ventricular morphologic response to {beta}-blockade with metoprolol in chronic left-ventricular systolic heart failure Eur J Heart Fail, October 1, 2002; 4(5): 635 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J G F Cleland Contemporary management of heart failure in clinical practice Heart, October 1, 2002; 88(90002): ii5 - 8. [Full Text] [PDF]
|
|
|
|
|
|
H F McIntyre, J Barrett, S Murphy, R Wray, S J Sutcliffe, and D M Walker Across the interface: the Hastings Heart Function Clinic Heart, October 1, 2002; 88(90002): ii23 - 27. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Coletta and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology -- WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME Eur J Heart Fail, December 1, 2001; 3(6): 747 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.P. Mohr, J.L.P. Thompson, R.M. Lazar, B. Levin, R.L. Sacco, K.L. Furie, J.P. Kistler, G.W. Albers, L.C. Pettigrew, H.P. Adams Jr., et al. A Comparison of Warfarin and Aspirin for the Prevention of Recurrent Ischemic Stroke N. Engl. J. Med., November 15, 2001; 345(20): 1444 - 1451. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ryden, M.L. Simoons, and J.P. Bassand Partnership in cardiovascular medicine. A key to success not only for professional organizations Eur. Heart J., October 2, 2001; 22(20): 1839 - 1843. [PDF]
|
|
|
|
 |
|
 J. G F Cleland, J. John, J. Dhawan, and A. Clark What is the optimal medical management of ischaemic heart failure? Br. Med. Bull., October 1, 2001; 59(1): 135 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Thackray, A. Coletta, P. Jones, A. Dunn, A. L. Clark, and J. G.F. Cleland Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF Eur J Heart Fail, August 1, 2001; 3(4): 491 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Louis, J. G.F. Cleland, S. Crabbe, S. Ford, S. Thackray, T. Houghton, and A. Clark Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001 Eur J Heart Fail, June 1, 2001; 3(3): 381 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P Reginelli and R. M Mills Non-cardiac surgery in the heart failure patient Heart, May 1, 2001; 85(5): 505 - 507. [Full Text]
|
|
|
|
|
|
S. D.R. Thackray, K. K.A. Witte, A. Khand, A. Dunn, A. L. Clark, and J. G.F. Cleland Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure Eur J Heart Fail, January 1, 2001; 3(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|